newsfilter
← Earnings
Earnings Releases·

Clene Inc. — Third Quarter 2026 Earnings Summary

Clene Inc. reported a net income of $3.9 million for the third quarter of 2026, a significant turnaround from the $8.8 million net loss recorded in the same period of 2025. The company submitted a New Drug Application to the FDA in October 2026 seeking accelerated approval for its investigational therapy CNM-Au8 for the treatment of amyotrophic lateral sclerosis. In September 2026, Clene completed a $4.0 million registered direct offering, which is expected to fund operations through the middle of the first quarter of 2027. Additionally, the company plans to initiate the Phase 3 RESTORE-ALS confirmatory trial in the second quarter of 2027 to evaluate the drug's effect on survival.

Company
CLENE INC
Sector
Healthcare
Industry
Biotechnology